Evogene Ltd. (NASDAQ:EVGN) Q4 2023 Results Conference Call March 7, 2024 9:00 AM ET Company Participants Ofer Haviv - President and Chief Executive Officer Yaron Eldad - Chief Financial Officer Yoash Zohar - CEO of Casterra Conference Call Participants Ben Klieve - Lake Street Capital Ben Haynor - Alliance Global Partners Brett Reiss - Janney Montgomery Scott Operator Ladies and gentlemen, thank you for standing by. Welcome to Evogene's Fourth Quarter and Full Year 2023 Results Conference Call. All particip ...

Evogene (EVGN) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.07 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 7.14%. A quarter ago, it was expected that this agricultural company would post a loss of $0.17 per share when it actually produced a loss of $0.08, delivering a surprise of 52.94%.Over the last four quarters, the company has surp ...

These agreements are expected to add approximately 400 tons in 2024 and establish long-term production infrastructure. Expanding the number of seed producers in various geographies with whom the company currently works is expected to lower production risks. Casterra's high-yield castor seed varieties, developed with Evogene's GeneRator AI tech-engine, are rigorously tested to meet industry standards. They are distinguished by exceptional cleanliness, successful phytosanitary test results, and an exceptional ...

Conference call scheduled for 9:00 AM ET REHOVOT, Israel, Feb. 26, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, announced today that it will release its financial results for the third quarter of 2023, on Thursday, March 7th, 2024. Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 ...

In collaboration with Bayer's Crop Science division, having an industry-leading R&D pipeline and portfolio of seeds & traits, crop protection, and digital farming solutions, AgPlenus will use its AI-driven computational modeling technology to design and optimize molecules identified for their broad-spectrum herbicidal activity targeting the APTH1 protein, a new mode of action identified by AgPlenus. Herbicide market is valued at $42.81 billion in 2024[1] and is crucial for ensuring global food security. It ...

Insects pose a major challenge to the health of crops worldwide, directly injuring plants as they feed on the plant's stems, fruit and roots, as well as indirectly by transmitting bacterial, viral and fungal infections to crops - costing the global economy an estimated $70 billion a year, according to the UN's Food and Agriculture Organization[1]. Experts predict such losses will worsen with global warming widening the spread of invasive insect risk and rising resistance to available insecticides. "Syngenta ...

The probiotics market is expected to double and reach approximately $114 billion by 2031 from approximately $55 billion in 2022[i]. The increased awareness of the microbiome, the bacteria living in and on the human body, has sparked significant interest in microbiome products based on supporting microbes for a healthier lifestyle. This collaboration aligns with the expanding importance of global microbiome research. The collaboration generates excellent synergy by combining Evogene's knowledge in bacterial- ...

Nir Arbel - CPO of Evogene Ofer Haviv Thank you, and good day, everyone. Today, I will review Evogene's activities, our financial stabilities and recent achievements. I will also provide an update on Evogene's potential catalyst expected in the near future. I will discuss some of our subsidiaries recent accomplishments and their positive impact on Evogene. Bear in mind that our subsidiaries leverage evidence technology as their main competitive advantage and their accomplishments demonstrate the power and t ...

Company Participants All forward-looking statements made herein speak only as of the date of the announcement of results. Many of the factors that impact whether forward-looking statements will come true are beyond the control of Evogene and may cause actual results to differ materially from anticipated results. We continued significant investment in Evogene ChemPass AI tech engine to strongly position us to forge strategic partnerships with industry leaders, expediting product development and delivering no ...

Company Participants Elran Haber - CEO, Biomica Ltd Ben Klieve - Lake Street Capital Markets Before we begin, I would like to caution that certain statements made during this earnings conference call by evidence management will constitute forward-looking statements that relate to future events, risks and uncertainties regarding business, strategy, operations and future performance and results of Evergene. All forward-looking statements made herein speak only as of the date of the announcement of results. Ma ...